March 27, 2009 - LifeVest, AutoPulse, Defibrillators and STEMI Solutions at ACC '09


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


Acceptance of World’s Only Wearable Defibrillator Continues to Expand for Those at Risk of Sudden Cardiac Arrest

March 27, 2009CHELMSFORD, Mass.—ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it will display its range of clinical resuscitation products—including the LifeVest® Wearable Defibrillator, the AutoPulse® Non-invasive Cardiac Support Pump, R Series® Code-Ready®, and STEMI solutions—in Booth #307 at the 2009 American College of Cardiology Conference March 29-31 at Orange County Convention Center in Orlando.  

The LifeVest, the first and only wearable defibrillator, is worn by patients at increased risk for sudden cardiac arrest (SCA), allowing their physicians time to decide how best to manage them long-term, including potentially the decision to implant a cardioverter defibrillator (ICD). At just 1.8 pounds, the LifeVest allows patients to easily return to their activities of daily living, while having the peace of mind that they are protected from SCA.   It is specifically approved by Medicare and other insurers for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk for cardiac arrest.  It may also be prescribed for patients whose comorbidities, including infections caused by placement of ICDs, prevent them undergoing immediate implant surgery for an ICD.

The LifeVest features a unique, non-invasive technology that continuously monitors the patient’s heart. If a life-threatening heart rhythm is detected, the device alerts the patient prior to delivering a shock.  The device releases a conductive gel onto the therapy electrodes to protect the skin, and then delivers a shock to restore normal heart rhythm.

“The entire event, from detecting a life-threatening arrhythmia to automatically delivering a defibrillation shock, usually occurs in less than a minute,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL.  “Timely defibrillation is the single most important factor in saving a SCA victim’s life. To date, the LifeVest has been prescribed for over 13,000 patients, and there have been almost 3,000 years of cumulative patient time wearing the LifeVest.”

 The AutoPulse Non-invasive Cardiac Support Pump is an automated, portable device with an easy-to-use, load-distributing LifeBand® that squeezes the entire chest, improving blood flow to the heart and brain during sudden cardiac arrest (SCA). The AutoPulse has been shown to improve survival to discharge in a major study published in the Journal of the American Medical Association (JAMA)*.

The only device of its kind, the AutoPulse delivers high-quality, uninterrupted chest compressions to maintain myocardial and cerebral perfusion, while freeing clinicians in the catheterization lab to perform procedures with optimal vascular access and minimal visual compromises. In the cath lab, using AutoPulse means no compromises between PCI and other actions. This exclusive technology offers the additional benefit of safeguarding staff from X-ray exposure as well as maintaining the integrity of a sterile working environment.”

Also on display will be ZOLL’s new R Series BLS and R Series Plus defibrillators, which are designed to extend simple, smart and ready defibrillation to every hospital department with advanced, cost-effective solutions for resuscitation. The R Series BLS is a simple, easy-to-use AED that becomes a full-featured, advanced life support device for critical care at the touch of a button. The R Series Plus, which also has both AED and ALS capabilities at the touch of a button, also has networking capabilities and See-Thru CPR®. Like all other ZOLL defibrillators, these models provide the Real CPR Help® feature.

The original R Series ALS, launched in November 2006, and these two new models, use the same uniform operating system common to all ZOLL defibrillators. The cables, paddles, batteries, handles, and electrodes are also common to ensure clinicians won’t encounter a mismatch in a time of crisis. 

In addition, all R Series models can use wireless networking to ensure code-readiness.  Based on standard WiFi technology, the R Series automatically sends a status of its state of readiness at a programmed time. Early notification maximizes patient safety by letting the clinician intervene before the defibrillator is needed for a code. 

Also on display will be the Company’s range of STEMI solutions that enable hospitals to rapidly transmit data from the field into the cath lab to assist clinicians in meeting ACC/AHA standards for door-to-balloon times.

About ZOLL Medical Corporation

ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the company’s resuscitation product development. For more information, visit

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, Code-Ready,  LifeBand, LifeVest, R Series, Real CPR Help,  And See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.

*Ong ME, Ornato JP et al. JAMA. 2006;295(22).